Wake up: Modern Strategies to Recognize and Combat Sleepiness in Narcolepsy and Idiopathic Hypersomnia - A Virtual Grand Round Series
In this 60 minute session, the freedom of virtual learning will allow one of 6 renown sleep specialists to visit your local community sleep clinic or freestanding neurology practice. Using survey data from experts regarding their preferred strategies in clinical scenarios and their thoughts on complicated questions (e.g., "is it clinically meaningful to distinguish narcolepsy type 2 and idiopathic hypersomnia"), presenters will work with your entire team to refine and enhance its management skills in patients with sleep disorders.
- Common pitfalls in the workup and diagnosis of narcolepsy and IH
- Therapeutic strategies (individual and combination) for patients with narcolepsy (types 1 and 2), and IH
- Emerging agents for narcolepsy and IH
- Examine clinical characteristics and variable diagnostic considerations of narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH) to improve condition differentiation and timely diagnosis.
- Identify the biologic mechanism underlying the overlapping effectiveness of traditional and low sodium oxybate in patients with NT1-, NT2-, and IH-associated EDS, and use this information to identify individuals that may be appropriate candidates for their use.
- Compare the patient selection for and clinical profiles of traditional (e.g., modafinil, SSRIs) and recently approved (e.g., pitolisant, solriamfetol, low sodium oxybate) agents for EDS secondary to narcolepsy and/or IH to discern how and for whom these agents can be effectively and safely prescribed.
Russell Rosenberg, PhD, D.ABSM (Chair)
Founder & Director
Atlanta School of Sleep Medicine and Technology
Director & CEO
NeuroTrials Research, Inc
Clete Kushida, MD, PhD, FASSM
Professor of Psychiatry and Behavioral Sciences
Palo Alto, CA
Heidi Riney, MD, D.ABPN
Fusion Sleep Center
Asim Roy, MD
Ohio Sleep Medicine Institute
Clinical Assistant Professor
Northeast Ohio Medical University
Michael Thorpy, MD
Director, Sleep-Wake Disorders Center
Montefiore Medical Center
Professor of Neurology
Albert Einstein College of Medicine
Phyllis Zee, MD, PhD
Director, Center for Circadian and Sleep Medicine
Chief, Division of Sleep Medicine
Feinberg School of Medicine
This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PIM designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.
Dr. Kushida reported the following financial relationships:
- Consulting Fees: Avadel Pharmaceuticals (Avadel), Jazz Pharmaceuticals (Jazz), XW Pharma
Dr. Rosenberg reported the following financial relationships:
- Consulting Fees: Harmony Biosciences (Harmony), Jazz, Takeda
- Contracted Research: Eisai Co. Ltd. (Eisai), Jazz, Suven Life Sciences (Suven), Takeda
Dr. Roy reported the following financial relationships:
- Consulting Fees: Avadel, Jazz, Harmony, Inspire Pharmaceuticals (Inspire)
- Fees for Non-CE Services: Eisai, Harmony, Jazz, Inspire
- Contracted Research: Avadel, Eisai, Harmony, Inspire, Jazz, Nyxoah, LiveNova
Dr. Thorpy reported the following financial relationships:
- Consultant/Advisory Board: Axsome Therapeutics, Balance Therapeutics, Eisai, Avadel, Harmony, Jazz, NLS Pharmaceuticals, Suven, Takeda, XW Pharma
Dr. Zee reported the following financial relationships:
- Royalty: Wolter-Kluwer
- Consulting Fees: Eisai, Harmony, Itamar Medical Ltd., Jazz, Takeda
- Contracted Research: Vanda Pharmaceuticals, Philips
- Ownership Interest: Teva Pharmaceuticals
Dr. Riney reported no relevant financial relationships.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by educational grants from Jazz Pharmaceuticals.